WBCPI 100.32 0.0% CBA 164.72 0.5801% BHP 38.06 0.9014% RIO 114.92 0.9576% CSL 241.89 0.8884% WBC 32.04 1.0726% NAB 35.11 0.6017% NEM 85.2 3.4608% WES 75.74 -0.0396% ANZ 28.84 1.5493% MQG 192.72 1.2291% GMG 28.74 0.8421% XYZ 88.34 -0.2484% RMD 36.08 8.5113% TLS 4.44 -0.4484% FMG 15.52 1.0417% TCL 13.89 0.072% ALL 64.25 0.0779% WOW 31.53 -0.3791% WDS 20.01 -2.0078%
Last update at 2025-04-24T06:10:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation
Mon 01 May 23, 08:00 PMWill PYC Therapeutics (ASX:PYC) Spend Its Cash Wisely?
Tue 22 Nov 22, 02:15 AMIs PYC Therapeutics Limited (ASX:PYC) Popular Amongst Insiders?
Sat 06 Aug 22, 10:29 PMWe're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely
Wed 08 Jun 22, 01:37 AMThose who invested in PYC Therapeutics (ASX:PYC) three years ago are up 256%
Mon 09 May 22, 12:53 AMWhat Is The Ownership Structure Like For PYC Therapeutics Limited (ASX:PYC)?
Sun 27 Feb 22, 10:46 PMPYC Therapeutics Limited (ASX:PYC) insider upped their holding by 0.06% earlier this year
Thu 30 Dec 21, 03:58 AMCompanies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Mon 15 Nov 21, 01:40 AMInvesting in PYC Therapeutics (ASX:PYC) five years ago would have delivered you a 785% gain
Thu 30 Sep 21, 12:40 AM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -23.35648M | -14.29397M | -18.63000M | -9.47524M | -6.98389M |
| Minority interest | 0.57M | 0.43M | 0.88M | 2.24M | 2.24M |
| Net income | -22.78899M | -14.32656M | -20.93958M | -7.07954M | -4.07977M |
| Selling general administrative | 2.54M | 4.38M | 6.18M | 5.67M | 1.83M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 15.81M | - | - | -1.90436M | -1.83717M |
| Reconciled depreciation | 0.55M | 0.84M | 0.62M | 0.55M | 0.13M |
| Ebit | -23.32919M | -14.26137M | -18.59118M | -9.74478M | -7.10210M |
| Ebitda | -22.77797M | -13.42187M | -17.96882M | -9.19766M | -6.97154M |
| Depreciation and amortization | 0.55M | 0.84M | 0.62M | 0.55M | 0.13M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -23.43091M | -14.26137M | -18.59118M | -9.74478M | -7.10210M |
| Other operating expenses | 39.22M | 30.21M | 21.83M | 9.74M | 7.10M |
| Interest expense | 0.03M | 0.03M | 0.04M | 0.53M | 0.12M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | -2.39571M | -2.90412M |
| Interest income | 0.08M | 0.02M | 0.11M | 0.21M | 0.12M |
| Net interest income | 0.05M | -0.00817M | 0.07M | 0.21M | 0.12M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.56749M | 0.03M | 2.31M | -2.39571M | -2.90412M |
| Total revenue | 15.81M | 16.07M | 3.08M | 0.06M | 0.00025M |
| Total operating expenses | 39.16M | 30.21M | 21.83M | 9.74M | 7.10M |
| Cost of revenue | - | - | - | 1.97M | 1.84M |
| Total other income expense net | 15.75M | -0.03259M | -0.03882M | 0.27M | 0.12M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -23.35648M | -14.29397M | -18.63000M | -7.07954M | -4.07977M |
| Net income applicable to common shares | -22.78899M | -13.86316M | -17.76759M | -6.82221M | -4.07977M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 91.24M | 37.17M | 45.35M | 57.94M | 31.55M |
| Intangible assets | - | 4.25M | 4.45M | 4.65M | 4.85M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.74M | 0.05M | 0.07M | 0.09M | 0.05M |
| Total liab | 10.18M | 8.72M | 5.15M | 4.02M | 1.35M |
| Total stockholder equity | 80.50M | 27.75M | 39.35M | 52.54M | 27.95M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.27M | 3.49M | 1.81M | 0.95M | 0.61M |
| Common stock | 230.58M | 140.09M | 125.99M | 125.99M | 87.21M |
| Capital stock | - | 140.09M | 125.99M | 125.99M | 87.21M |
| Retained earnings | -155.89485M | -118.16944M | -95.38045M | -81.51729M | -63.74971M |
| Other liab | - | 0.18M | 0.08M | 0.18M | - |
| Good will | - | - | - | - | - |
| Other assets | - | 0.00000M | 0.02M | 0.02M | - |
| Cash | 66.87M | 15.57M | 29.11M | 18.44M | 6.94M |
| Cash and equivalents | - | 15.57M | 29.11M | 18.44M | 7.24M |
| Total current liabilities | 9.11M | 8.41M | 4.39M | 3.30M | 0.71M |
| Current deferred revenue | - | -0.17782M | -0.25980M | -0.18753M | -0.15297M |
| Net debt | -65.76179M | -15.25605M | -28.16626M | -17.70484M | -6.14420M |
| Short term debt | 0.31M | 0.18M | 0.26M | 0.19M | 0.15M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 1.11M | 0.32M | 0.94M | 0.73M | 0.80M |
| Other stockholder equity | - | -21.91791M | -30.61088M | -44.47404M | -23.45712M |
| Property plant equipment | - | 1.04M | 1.63M | 1.49M | 1.14M |
| Total current assets | 85.61M | 31.87M | 39.25M | 51.78M | 25.26M |
| Long term investments | - | - | - | - | 0.30M |
| Net tangible assets | - | 23.50M | 34.90M | 48.39M | 23.10M |
| Short term investments | - | - | 0.00000M | 33.07M | 18.19M |
| Net receivables | 18.00M | 16.25M | 10.07M | 0.19M | 0.08M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | -0.04270M |
| Accounts payable | 7.53M | 4.92M | 2.57M | 2.35M | 0.10M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 5.81M | 5.83M | 8.74M | 8.07M | 4.50M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 87.21M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 4.05M | -5.29275M | 0.02M | 0.02M | 0.30M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 5.62M | 5.29M | 6.10M | 6.16M | 6.29M |
| Capital lease obligations | - | 0.32M | 0.94M | 0.73M | 0.80M |
| Long term debt total | - | 0.14M | 0.68M | 0.54M | 0.65M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -0.47712M | 33.07M | -14.88134M | -13.66620M | -4.51955M |
| Change to liabilities | 4.34M | 0.26M | 2.50M | 0.02M | -1.33436M |
| Total cashflows from investing activities | -0.47712M | 32.68M | -15.52169M | -13.77230M | -4.97684M |
| Net borrowings | -0.23279M | -0.18236M | -0.22664M | -0.14520M | -0.14520M |
| Total cash from financing activities | 11.44M | -0.18236M | 38.56M | 25.11M | 8.62M |
| Change to operating activities | -0.13995M | 0.53M | 0.22M | 0.13M | 0.06M |
| Net income | -22.78899M | -13.86316M | -17.76759M | -6.82221M | -4.07977M |
| Change in cash | -13.53849M | 10.67M | 11.19M | 5.28M | 3.03M |
| Begin period cash flow | 29.11M | 18.44M | 7.24M | 1.66M | 3.15M |
| End period cash flow | 15.57M | 29.11M | 18.44M | 6.94M | 6.18M |
| Total cash from operating activities | -24.42169M | -21.78228M | -11.79131M | -5.74840M | -5.11607M |
| Issuance of capital stock | 12.65M | - | 41.08M | 26.88M | 9.12M |
| Depreciation | 0.88M | 0.84M | 0.62M | 0.55M | 0.13M |
| Other cashflows from investing activities | 0.01M | 33.07M | -0.04932M | -13.66620M | -4.51930M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -6.16265M | -9.83360M | -0.13333M | -0.09605M | -0.01583M |
| Sale purchase of stock | -0.97625M | -0.97625M | -2.29467M | -1.62499M | -0.50320M |
| Other cashflows from financing activities | -0.23279M | -0.18236M | -0.22664M | -0.14520M | -0.45729M |
| Change to netincome | -0.55422M | 0.18M | 2.77M | 0.47M | 0.11M |
| Capital expenditures | 0.49M | 0.39M | 0.59M | 0.11M | 0.46M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -6.16265M | -9.83360M | -0.13333M | -0.09605M | 3.01M |
| Stock based compensation | -0.07030M | 0.61M | 3.63M | 0.72M | - |
| Other non cash items | -2.51475M | -8.75907M | 5.35M | 0.53M | 3.95M |
| Free cash flow | -24.91280M | -22.16919M | -12.38234M | -5.85450M | -5.57361M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| PYC PYC Therapeutics Ltd |
0.09 8.25% | 1.11 | - | - | 24.58 | 11.08 | -8.4071 | |
| CSL CSL Ltd |
2.13 0.89% | 241.89 | 28.32 | 33.33 | 7.69 | 4.02 | 5.79 | 17.98 |
| TLX Telix Pharmaceuticals Ltd |
0.24 0.85% | 28.56 | 190.40 | 64.94 | 12.21 | 16.82 | 12.04 | 101.90 |
| MSB Mesoblast Ltd |
0.09 5.29% | 1.79 | - | 454.55 | 400.93 | 3.14 | 271.18 | -9.8623 |
| NEU Neuren Pharmaceuticals Ltd |
0.33 3.00% | 11.34 | 10.40 | 66.67 | 6.69 | 3.99 | 5.76 | 7.00 |
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Harry Perkins Inst. of Medical Research, Nedlands, WA, Australia, 6009
| Name | Title | Year Born |
|---|---|---|
| Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) | CEO & Exec. Director | 1983 |
| Mr. Andrew Taylor B.Com., C.A. | Chief Financial Officer | NA |
| Prof. Sue Fletcher | Chief Scientific Officer | NA |
| Dr. May Orfali M.B.A., M.D. | Chief Medical Officer of US Operations | 1968 |
| Dr. Glenn Noronha | Chief Devel. Officer | 1965 |
| Mr. Kevin Ronald Hart B.Com, B.Comm (Hons), C.A., F.C.A., FCA | Company Sec. | 1962 |
| Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) | CEO & Executive Director | 1983 |
| Mr. Andrew Taylor B.Com., C.A. | CFO & Company Secretary | NA |
| Mr. Kevin Ronald Hart B.Com., B.Comm (Hons), C.A., F.C.A. | Company Secretary | 1962 |
| Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) | CEO & Executive Director | 1983 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
NZ
CA
UK
US
AU
IND
Please wait processing your request...